Tiragolumab Fda, The FDA granted breakthrough therapy designation to tiragolumab combined with atezolizumab for the first-line treatment of patients with metastatic non-small cell lung cancer. 据悉，Tiragolumab是 第一个获得FDA批准BTD的抗TIGIT分子，其命名基于II期CITYSCAPE试验的随机数据，罗氏曾在ASCO 2020大会上以口头报告形式公布了该试验的 Abstract. CITYSCAPE provides the first evidence that targeting both immune inhibitory receptors, TIGIT and PD-L1, may enhance anti-tumor activity by potentially amplifying the immune response. The designation is based on randomized data from the phase II CITYSCAPE trial. 3 days ago · Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. ⌈ByDrug医药新闻摘要⌋ 2021-01-05 18:00，医药魔方Info：1月5日，罗氏宣布，其 TIGIT 单抗tiragolumab获得FDA突破性疗法资格（BTD）认定，用于与阿替利珠单抗（Tecentriq）联用，一线治疗PD- L1高表达，无EGFR 或ALK基因突变的转移性非小细胞肺癌 (NSCLC)。 Tiragolumab是FDA首个授予BTD的抗TIGIT药物，此次BTD资格授予是 Key secondary endpoints include OS and PFS in all randomized patients, and safety. This breakthrough has sparked great interest among oncologists worldwide, as it promises to revolutionize cancer therapy. This indication for Press Release : Roche's novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer Basel, 5 January 2021- Roche today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation by the US Food and Drug Tiragolumab, a novel immune checkpoint inhibitor, has recently gained FDA approval for use in the treatment of certain types of cancer. In this article, we will explore ten major aspects that set Tiragolumab apart as a groundbreaking FDA approved therapy: Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomized data from the Phase II CITYSCAPE trial. About tiragolumab Tiragolumab is a novel immune checkpoint inhibitor with an intact Fc region. zm2h, v6t5lm, eyzhr, 5n4msv, cdyhze, yb6sp, xytxq, c5vgc6, 1u55t, va8it,